the Scottsdale Community Clinical Oncology Program (CCOP) continuation application is proposed by a multidisciplinary consortium of medical professionals dedicated to high quality clinical cancer treatment, prevention and control research. The three consortium components include Scottsdale Memorial Hospital-North, Mayo Clinical Scottsdale, and United Blood Services of Arizona. This application responds to a need to continue to bring benefits of the National Cancer Program to the substantial population of our large regional referral area in the southwestern U.S. Our primary research base is the North Central Cancer Treatment Group (NCCTG). Additional research base memberships include the Eastern Cooperative Oncology Group (ECOG) and the Univ. of Rochester Cancer Center. Achievements since the onset of our grant funding in late 1993 include; 1) activation of the Prostate Cancer Prevention Trial through an independent application to the Southwest Oncology Group 2) activation of the intergroup Colorectal Cancer Prevention Trial 3) National Surgical Adjuvant Breast and Bowel Project approval of our participation in the Breast Cancer Prevention Trial 4) development of the Mayo Clinic Scottsdale Breast Diseases Center to improve access for women with breast cancer and/or significant risks for the development of breast cancer 5) initiatives to increase the protocol recruitment of women and minorities including the Familial Cancer Project of the Mayo Women's Program 6) certification as an ECOG Bone Marrow Transplantation Center.
Specific aims i nclude further facilitating the availability of cancer treatment, prevention and control research protocols to the diverse patient population in our referral area. This project will continue to speed the transfer of newly developed cancer intervention technologies to reduce cancer morbidity and mortality in our region. The Scottsdale CCOP has increased the accrual of patients to cancer prevention and control protocols. Scottsdale CCOP organization has an outstanding, established record of increasing the numbers of patients accrued to NCI approved protocols, particularly cancer prevention and cancer control protocols, during the past 5 years. We have exceeded CCOP grant expectations for patient accruals and case credits to NCI approved cancer treatment and cancer prevention and control protocols. We have achieved the specific aims of the 1992 CCOP Request for Application (RFA), and developed an estimable operational plan for reaching the goals of this RFA. The Scottsdale CCOP organization has contributed to a number of important clinical cancer research findings and publications as noted in this application. We confidently predict the Scottsdale CCOP will enter more than 100 patient per year on clinical cancer treatment research protocols, an more than 75 patients per year on clinical cancer prevention and control protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
7U10CA060276-05
Application #
2429781
Study Section
Special Emphasis Panel (SRC (15))
Project Start
1993-09-30
Project End
2001-05-31
Budget Start
1997-06-01
Budget End
1998-05-31
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Mayo Clinic, Arizona
Department
Type
DUNS #
City
Scottsdale
State
AZ
Country
United States
Zip Code
85259
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Crozier, Jennifer A; Advani, Pooja P; LaPlant, Betsy et al. (2016) N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. Clin Breast Cancer 16:23-30
Galanis, Evanthia; Anderson, S Keith; Lafky, Jackie M et al. (2013) Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 19:4816-23
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Atherton, Pamela J; Halyard, Michele Y; Sloan, Jeff A et al. (2013) Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA. Support Care Cancer 21:1193-9
Barton, Debra L; Liu, Heshan; Dakhil, Shaker R et al. (2013) Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105:1230-8
Bolton, John S; O'Connell, Michael J; Mahoney, Michelle R et al. (2012) Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Clin Colorectal Cancer 11:31-7
Laack, Nadia N; O'Neill, Brian Patrick; Ballman, Karla V et al. (2011) CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys 81:476-82
Barton, Debra L; Soori, Gamini S; Bauer, Brent A et al. (2010) Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 18:179-87
Moraska, Amanda R; Atherton, Pamela J; Szydlo, Daniel W et al. (2010) Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol 8:128-32

Showing the most recent 10 out of 97 publications